Loading...
ROCO
4147
Market cap583mUSD
Nov 13, Last price  
66.80TWD
Name

TaiMed Biologics Inc

Chart & Performance

D1W1MN
ROCO:4147 chart
P/E
—
P/S
29.91
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.96%
Rev. gr., 5y
-2.83%
Revenues
610m
+24.07%
00135,00000002,076,0008,436,000241,041,000704,504,000722,485,000413,442,000563,008,000491,777,000610,162,000
Net income
-202m
L+3.60%
-220,815,000-238,207,000-204,520,000-207,298,000-251,677,000-281,735,000-471,680,000-281,962,000-524,554,000-321,710,000-579,010,000-187,392,000-478,377,000-279,388,000-194,810,000-201,832,000
CFO
-380m
L+1,382.57%
-171,313,000-186,925,000-134,413,000-117,231,000-164,684,000-213,084,000-446,265,000-172,295,000-516,483,000-522,856,000-655,314,000-201,936,000-211,275,000-605,210,000-25,601,000-379,552,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.
URL
http://www.taimedbiologics.com/
IPO date
Jun 28, 2010
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT